What Does Enalapril Deplete? 1 Nutrients Affected

Enalapril is an ACE inhibitor prescribed to approximately 8 million Americans annually under brand names Vasotec and Epaned for hypertension, heart failure, asymptomatic left ventricular dysfunction, and diabetic nephropathy. According to ChEMBL mechanism-of-action data, enalapril is an angiotensin-converting enzyme inhibitor with Phase 4 indications for hypertension and cardiovascular diseases. Enalapril is a prodrug that is converted to its active form enalaprilat by hepatic esterases. With oral bioavailability of 40%, peak plasma concentration of 69 ng/mL at 1 hour, 50% protein binding, and an elimination half-life of 2.5 hours for enalapril itself (though enalaprilat has a longer effective duration of approximately 11 hours), the drug provides sustained ACE inhibition throughout the dosing interval. The active metabolite enalaprilat binds to the zinc atom in the ACE active site, which is the molecular basis for both the drug's therapeutic action and its zinc-depleting effect.

The Comparative Toxicogenomics Database catalogs 84 gene interactions for enalapril, with 4,623 total disease associations and 192 curated disease links. ACE is a zinc-dependent metalloenzyme — it requires a zinc atom in its catalytic center to function. When enalaprilat binds to this zinc atom to inhibit ACE, it disrupts normal zinc handling at the enzyme level and increases urinary zinc excretion. This is the only documented nutrient depletion from ACE inhibitors, making enalapril one of the cleanest cardiovascular medications from a nutrient perspective. However, the single zinc depletion is clinically meaningful because zinc serves as a cofactor for over 300 enzymes in the body, affecting immune function, DNA synthesis, wound healing, protein synthesis, and taste perception. The characteristic ACE inhibitor dry cough, caused by bradykinin accumulation, is not a nutrient depletion issue but is the most common reason patients switch to ARBs.

PharmGKB pharmacogenomic annotations include 10 entries for enalapril, linking genes including ACE, BDKRB2, NOS3, VEGFA, and CES1 to drug efficacy and toxicity in hypertension and cardiovascular disease. The BDKRB2 annotation is notable for linking the bradykinin receptor gene to both efficacy and the cough toxicity that drives treatment changes. Across 532 randomized controlled trials involving 580,358 patients in enalapril research indexed by CTD, the evidence base for cardiovascular protection is among the strongest for any ACE inhibitor. Across 212 million rows in Kelda's database, enalapril's single-nutrient depletion profile makes it one of the most nutrient-friendly cardiovascular medications available. The key clinical takeaway is simple: supplement zinc 15-30mg daily with food, monitor serum zinc levels annually, and the one depletion from this otherwise well-tolerated medication is easily managed.